# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name o	of entity	
ImExl	HS Limited	
ABN		
60 09	6 687 839	
We (t	he entity) give ASX the following	information.
	1 - All issues ust complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Unlisted Options
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	2,000,000
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Unlisted options exercisable at \$0.053 each and expiring 9 December 2023. The options are subject to the following vesting conditions:  500,000 to vest 2 years from the date of appointment; and 1,500,000 to vest 3 years from the date of appointment,
		(in each case subject to continuous service to the Company as a Non-Executive Director during the

period from the date of appointment up to and

including the applicable vesting date).

No – but shares issued upon exercise of options Do the +securities rank equally in 4 will rank equally in respects from the date of issue all respects from the +issue date with existing fully paid ordinary shares. with an existing +class of quoted +securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend. distribution or interest payment Issue price or consideration Nil 5 Options issued in accordance with terms and 6 Purpose of the issue (If issued as consideration for the conditions of the appointment of Dr Lingard as a acquisition of assets, clearly Non-Executive Director. identify those assets) 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed 6c Number of +securities issued 2,000,000 without security holder approval under rule 7.1 6d N/A Number of \*securities issued with security holder approval under rule 7.1A 6e Number of \*securities issued N/A with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to Annexure 1	
7	<sup>+</sup> Issue dates	10 December 2018	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.		
	33 11		
8	Number and +class of all +securities quoted on ASX (including the +securities in	Number 395,657,180	+Class Fully paid ordinary Shares
	section 2 if applicable)	2,500,006	Options exercisable at \$1.00 on or before 31 December 2018

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
530,000,000	Fully paid ordinary
	shares escrowed 24
	months from re-
	quotation
3,000,000	Class A Performance
	Shares
35,000,000	Options exercisable at
	\$0.025 expiring 31/3/2021
50,000,000	Class A Consideration
, ,0000,000	Options exercisable at
	\$0.05, expiring 30/6/2021
	and escrowed 24 months
	from re-quotation
50,000,000	Class B Consideration
	Options exercisable at
	\$0.0375, expiring 28/8/2023, escrowed 24
	months from re-
	quotation and subject to
	vesting conditions.
50,000,000	Class C Consideration
	Options exercisable at
	\$0.0375, expiring
	28/8/2023, escrowed 24 months from re-
	months from requotation and subject to
	vesting conditions.
12,500,000	New Options exercisable
	at \$0.0375, expiring
	30/6/2021 and are subject
	to escrow until 14 May
	2019.
30,000,000	Adviser Options
	exercisable at \$0.05,
	expiring 30/6/2021 and
	escrowed 24 months
	from re-quotation
4 000 000	Unlisted Options
4,000,000	exercisable at \$0.07,
	expiring 25/10/2023 and
	subject to vesting
	conditions.
2,000,000	Unlisted Options
	exercisable at \$0.053,
	expiring 9/12/2023 and subject to vesting
	conditions.
	conditions.

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A
Part :	2 - Pro rata issue	
11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

20	Names of any underwriters	
21	Amount of any underwriting fee	
21	or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
2.4	Amount of any handling foo	
24	Amount of any handling fee payable to brokers who lodge	
	acceptances or renunciations on	
	behalf of security holders	
25	If the issue is contingent on	
,	security holders' approval, the	
	date of the meeting	
26	Date entitlement and acceptance	
	form and offer documents will be	
	sent to persons entitled	
27	If the entity has issued options,	
-/	and the terms entitle option	
	holders to participate on exercise,	
	the date on which notices will be sent to option holders	
	,	
28	Date rights trading will begin (if	
	applicable)	
29	Date rights trading will end (if	
	applicable)	
30	How do security holders sell their	
	entitlements in full through a broker?	
	DIUNCI:	
31	How do security holders sell part	
	of their entitlements through a	
	broker and accept for the balance?	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Issue date	
	3 - Quotation of securitied only complete this section if you are app	
34	Type of *securities (tick one)	
(a)	+Securities described in Part	.1
(b)		nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
	es that have ticked box 34(a) ional securities forming a new	class of securities
Tick to docum	o indicate you are providing the informa nents	tion or
35	1 1	securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36	1 1	v securities, a distribution schedule of the additional umber of holders in the categories
37	A copy of any trust deed for	the additional *securities

### Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		\r_1	+ Cl
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number	+Class

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Company secretary)	Date: 10 December 2018
Print name:	Peter Webse	

04/03/2013 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	150,657,180	
<ul> <li>Add the following:         <ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul> </li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> </ul>	775,000,000 shares as approved by shareholders on 31 July 2018	
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items  Subtract the number of fully paid  ordinary securities cancelled during that 12 month period	-	
"A"	925,657,180	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	138,848,577	
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule	
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	4,000,000 unlisted options issued 25/10/18 2,000,000 unlisted options issued 10/12/18	
• Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	6,000,000	
Step 4: Subtract "C" from ["A" x ' placement capacity under rule 7.1	<u>-</u>	
"A" x 0.15	138,848,577	
Note: number must be same as shown in Step 2		
Subtract "C"	6,000,000	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	132,848,577	
	[Note: this is the remaining placement capacity under rule 7.1]	

04/03/2013 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.

## Part 2 - N/A

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Step 2: Calculate 10% of "A"	
"D"	0.10  Note: this value cannot be changed
<b>Multiply</b> "A" by 0.10	
7.1A that has already been used  Insert number of *equity securities issued or agreed to be issued in that 12 month	t of placement capacity under rule
<ul> <li>period under rule 7.1A</li> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with</li> </ul>	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

04/03/2013 Appendix 3B Page 13

<sup>+</sup> See chapter 19 for defined terms.